Abstract
METHODS: The VEGF165 DNA fragment was inserted into a green fluorescent protein fusion vector, which was then transfected into endothelial cells and cardiac myocytes with lipofectamine.
AIM: To study the feasibility of VEGF165 gene transfection to endothelial cells and cardiac myocytes in-vitro.
RESULTS: The endothelial cells and cardiac myocytes were successfully transfected with pIRES2-EGFP-hVEGF165 gene, which was confirmed by fluoroscopy and immunohistochemistry.
CONCLUSION: VEGF can be expressed stably in the endothelial cells and cardiac myocytes, which might be useful for the gene therapy of myocardial ischemia.
| Original language | English |
|---|---|
| Pages (from-to) | 223-224 |
| Number of pages | 2 |
| Journal | Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology |
| Volume | 19 |
| Issue number | 3 |
| State | Published - 1 May 2003 |
| Externally published | Yes |